With the accelerated transition from existing propellants HFA-134a and HFA-227ea, switching to alternative low Global Warming Potential (GWP) propellants in pressurised Metered Dose Inhalers (pMDIs) is an urgent industry priority. Companies must be ready to adapt their manufacturing, clinical testing and regulatory submission processes, and getting ahead of the curve now will pay dividends later. Appropriate planning and expert guidance are vital for ensuring continuity of supply for patients while charting a course for success.
Following the publication of “Championing a Safe Transition to Low Carbon Inhalers” in Pharmaceutical Manufacturing and Packing Sourcer (PMPS), we are excited to dig deeper into the logistics of transitioning to the next generation of propellants. We convened an expert panel to explore the key success factors, and the result was this fascinating roundtable discussion.
Expert Panel
Nick Atkinson
Markus Laubscher
Paul Sullivan
Why this roundtable?
This exclusive roundtable offers practical insight into the current challenges faced by the industry experts already pioneering the green transition. Featuring thought leaders from Bespak, DH Industries and Orbia, the panel uniquely focuses on hidden challenges and retrospective learning to better support the industry in its adoption of next-generation propellants.
In a concise 30-minute discussion the panel share their essential learnings on:
The current industry landscape and factors driving the transition forward
Blind spots to watch out for when planning for the transition
Considerations for in-house investment and outsourcing
Navigating complex and changing regulatory environments
Scaling small-batch testing to commercial production with next-generation propellants
Tackling the updated safety and handling requirements
Ensuring continuous supply of vital medicines for patients during the transition
Fill out the form to access our roundtable:
